{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:55:50Z","timestamp":1780498550261,"version":"3.54.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s10067-025-07390-3","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T07:20:26Z","timestamp":1741591226000},"page":"1527-1536","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparative analysis of clinical profile, therapeutic management, and clinical prognosis of patients with seropositive or seronegative rheumatoid arthritis following the introduction of a first targeted therapy in a real-life setting"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3495-3817","authenticated-orcid":false,"given":"L\u00e9onard","family":"Angelozzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Gillibert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Brevet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Grosjean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Darmoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Jouen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Lequerr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Vittecoq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,10]]},"reference":[{"key":"7390_CR1","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","volume":"376","author":"DL Scott","year":"2010","unstructured":"Scott DL, Wolfe F, Huizinga TWJ (2010) Rheumatoid arthritis. Lancet Lond Engl 376:1094\u20131108. https:\/\/doi.org\/10.1016\/S0140-6736(10)60826-4","journal-title":"Lancet Lond Engl"},{"key":"7390_CR2","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1136\/annrheumdis-2015-208870","volume":"76","author":"S Ajeganova","year":"2017","unstructured":"Ajeganova S, van Steenbergen HW, Verheul MK, Forslind K, Hafstr\u00f6m I, Toes REM et al (2017) The association between anti-carbamylated protein (anti-CarP) antibodies and radiographic progression in early rheumatoid arthritis: a study exploring replication and the added value to ACPA and rheumatoid factor. Ann Rheum Dis 76:112\u2013118. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208870","journal-title":"Ann Rheum Dis"},{"key":"7390_CR3","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jbspin.2018.10.002","volume":"86","author":"C Daien","year":"2019","unstructured":"Daien C, Hua C, Gaujoux-Viala C, Cantagrel A, Dubremetz M, Dougados M et al (2019) Update of French society for rheumatology recommendations for managing rheumatoid arthritis. Joint Bone Spine 86:135\u2013150. https:\/\/doi.org\/10.1016\/j.jbspin.2018.10.002","journal-title":"Joint Bone Spine"},{"key":"7390_CR4","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.3899\/jrheum.140082","volume":"41","author":"L Barra","year":"2014","unstructured":"Barra L, Pope JE, Orav JE, Boire G, Haraoui B, Hitchon C et al (2014) Prognosis of seronegative patients in a large prospective cohort of patients with early inflammatory arthritis. J Rheumatol 41:2361\u20132369. https:\/\/doi.org\/10.3899\/jrheum.140082","journal-title":"J Rheumatol"},{"key":"7390_CR5","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1136\/ard.2009.116384","volume":"69","author":"D van der Woude","year":"2010","unstructured":"van der Woude D, Syversen SW, van der Voort EIH, Verpoort KN, Goll GL, van der Linden MPM et al (2010) The ACPA isotype profile reflects long-term radiographic progression in rheumatoid arthritis. Ann Rheum Dis 69:1110\u20131116. https:\/\/doi.org\/10.1136\/ard.2009.116384","journal-title":"Ann Rheum Dis"},{"key":"7390_CR6","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1093\/rheumatology\/kei203","volume":"45","author":"MA Quinn","year":"2006","unstructured":"Quinn MA, Gough AKS, Green MJ, Devlin J, Hensor EMA, Greenstein A et al (2006) Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome. Rheumatol Oxf Engl 45:478\u2013480. https:\/\/doi.org\/10.1093\/rheumatology\/kei203","journal-title":"Rheumatol Oxf Engl"},{"key":"7390_CR7","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/acr.24071","volume":"72","author":"E Alemao","year":"2020","unstructured":"Alemao E, Bao Y, Weinblatt ME, Shadick N (2020) Association of seropositivity and mortality in rheumatoid arthritis and the impact of treatment with disease-modifying antirheumatic drugs: results from a real-world study. Arthritis Care Res 72:176\u2013183. https:\/\/doi.org\/10.1002\/acr.24071","journal-title":"Arthritis Care Res"},{"key":"7390_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000406","volume":"3","author":"C Hua","year":"2017","unstructured":"Hua C, Daien CI, Combe B, Landewe R (2017) Diagnosis, prognosis and classification of early arthritis: results of a systematic review informing the 2016 update of the EULAR recommendations for the management of early arthritis. RMD Open 3:e000406. https:\/\/doi.org\/10.1136\/rmdopen-2016-000406","journal-title":"RMD Open"},{"key":"7390_CR9","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1136\/ard.2003.017574","volume":"63","author":"L De Rycke","year":"2004","unstructured":"De Rycke L, Peene I, Hoffman IEA, Kruithof E, Union A, Meheus L et al (2004) Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis 63:1587\u20131593. https:\/\/doi.org\/10.1136\/ard.2003.017574","journal-title":"Ann Rheum Dis"},{"key":"7390_CR10","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00296-019-04492-5","volume":"40","author":"J Grosse","year":"2020","unstructured":"Grosse J, Allado E, Roux C, Pierreisnard A, Couderc M, Clerc-Urmes I et al (2020) ACPA-positive versus ACPA-negative rheumatoid arthritis: two distinct erosive disease entities on radiography and ultrasonography. Rheumatol Int 40:615\u2013624. https:\/\/doi.org\/10.1007\/s00296-019-04492-5","journal-title":"Rheumatol Int"},{"key":"7390_CR11","doi-asserted-by":"publisher","first-page":"R249","DOI":"10.1186\/ar4092","volume":"14","author":"B Fautrel","year":"2012","unstructured":"Fautrel B, Granger B, Combe B, Saraux A, Guillemin F, Le Loet X (2012) Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort. Arthritis Res Ther 14:R249. https:\/\/doi.org\/10.1186\/ar4092","journal-title":"Arthritis Res Ther"},{"key":"7390_CR12","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1136\/annrheumdis-2015-208873","volume":"76","author":"LB Nordberg","year":"2017","unstructured":"Nordberg LB, Lillegraven S, Lie E, Aga A-B, Olsen IC, Hammer HB et al (2017) Patients with seronegative RA have more inflammatory activity compared with patients with seropositive RA in an inception cohort of DMARD-na\u00efve patients classified according to the 2010 ACR\/EULAR criteria. Ann Rheum Dis 76:341\u2013345. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208873","journal-title":"Ann Rheum Dis"},{"key":"7390_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195550","volume":"13","author":"S Choi","year":"2018","unstructured":"Choi S, Lee K-H (2018) Clinical management of seronegative and seropositive rheumatoid arthritis: a comparative study. PLoS ONE 13:e0195550. https:\/\/doi.org\/10.1371\/journal.pone.0195550","journal-title":"PLoS ONE"},{"key":"7390_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000752","volume":"4","author":"LB Nordberg","year":"2018","unstructured":"Nordberg LB, Lillegraven S, Aga A-B, Sexton J, Olsen IC, Lie E et al (2018) Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR\/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial. RMD Open 4:e000752. https:\/\/doi.org\/10.1136\/rmdopen-2018-000752","journal-title":"RMD Open"},{"key":"7390_CR15","doi-asserted-by":"publisher","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D et al EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 2022:ard-2022\u2013223356. https:\/\/doi.org\/10.1136\/ard-2022-223356","DOI":"10.1136\/ard-2022-223356"},{"key":"7390_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0089442","volume":"9","author":"Q Lv","year":"2014","unstructured":"Lv Q, Yin Y, Li X, Shan G, Wu X, Liang D et al (2014) The status of rheumatoid factor and anti-cyclic citrullinated peptide antibody are not associated with the effect of anti-TNF\u03b1 agent treatment in patients with rheumatoid arthritis: a meta-analysis. PLoS ONE 9:e89442. https:\/\/doi.org\/10.1371\/journal.pone.0089442","journal-title":"PLoS ONE"},{"key":"7390_CR17","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1093\/rheumatology\/keaa393","volume":"60","author":"DS Courvoisier","year":"2021","unstructured":"Courvoisier DS, Chatzidionysiou K, Mongin D, Lauper K, Mariette X, Morel J et al (2021) The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries. Rheumatol Oxf Engl 60:820\u2013828. https:\/\/doi.org\/10.1093\/rheumatology\/keaa393","journal-title":"Rheumatol Oxf Engl"},{"key":"7390_CR18","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1136\/annrheumdis-2011-201117","volume":"72","author":"JD Isaacs","year":"2013","unstructured":"Isaacs JD, Cohen SB, Emery P, Tak PP, Wang J, Lei G et al (2013) Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann Rheum Dis 72:329\u2013336. https:\/\/doi.org\/10.1136\/annrheumdis-2011-201117","journal-title":"Ann Rheum Dis"},{"key":"7390_CR19","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1002\/art.39595","volume":"68","author":"JE Gottenberg","year":"2016","unstructured":"Gottenberg JE, Courvoisier DS, Hernandez MV, Iannone F, Lie E, Canh\u00e3o H et al (2016) Brief report: association of rheumatoid factor and anti-citrullinated protein antibody positivity with better effectiveness of abatacept: results from the pan-European Registry Analysis. Arthritis Rheumatol Hoboken NJ 68:1346\u20131352. https:\/\/doi.org\/10.1002\/art.39595","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"7390_CR20","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1007\/s10067-022-06176-1","volume":"41","author":"R Alten","year":"2022","unstructured":"Alten R, Mariette X, Flipo R-M, Caporali R, Buch MH, Patel Y et al (2022) Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study. Clin Rheumatol 41:2361\u20132373. https:\/\/doi.org\/10.1007\/s10067-022-06176-1","journal-title":"Clin Rheumatol"},{"key":"7390_CR21","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1007\/s10067-019-04449-w","volume":"38","author":"R Alten","year":"2019","unstructured":"Alten R, Mariette X, Lorenz H-M, N\u00fc\u00dflein H, Galeazzi M, Navarro F et al (2019) Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study. Clin Rheumatol 38:1413\u20131424. https:\/\/doi.org\/10.1007\/s10067-019-04449-w","journal-title":"Clin Rheumatol"},{"key":"7390_CR22","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.jbspin.2014.02.014","volume":"81","author":"A Frazier-Mironer","year":"2014","unstructured":"Frazier-Mironer A, Dougados M, Mariette X, Cantagrel A, Deschamps V, Flipo RM et al (2014) Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice. Joint Bone Spine 81:352\u2013359. https:\/\/doi.org\/10.1016\/j.jbspin.2014.02.014","journal-title":"Joint Bone Spine"},{"key":"7390_CR23","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1136\/ard.2006.060608","volume":"66","author":"F Bobbio-Pallavicini","year":"2007","unstructured":"Bobbio-Pallavicini F, Caporali R, Alpini C, Avalle S, Epis OM, Klersy C et al (2007) High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis. Ann Rheum Dis 66:302\u2013307. https:\/\/doi.org\/10.1136\/ard.2006.060608","journal-title":"Ann Rheum Dis"},{"key":"7390_CR24","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.1002\/art.30596","volume":"63","author":"P Lal","year":"2011","unstructured":"Lal P, Su Z, Holweg CTJ, Silverman GJ, Schwartzman S, Kelman A et al (2011) Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment. Arthritis Rheum 63:3681\u20133691. https:\/\/doi.org\/10.1002\/art.30596","journal-title":"Arthritis Rheum"},{"key":"7390_CR25","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3899\/jrheum.131279","volume":"41","author":"De Keyser F, Hoffman I, Durez P, Kaiser M-J, Westhovens R, MIRA Study Group","year":"2014","unstructured":"De Keyser F, Hoffman I, Durez P, Kaiser M-J, Westhovens R, MIRA Study Group (2014) Longterm followup of rituximab therapy in patients with rheumatoid arthritis: results from the Belgian MabThera in Rheumatoid Arthritis registry. J Rheumatol 41:1761\u20131765. https:\/\/doi.org\/10.3899\/jrheum.131279","journal-title":"J Rheumatol"},{"key":"7390_CR26","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1002\/art.30233","volume":"63","author":"J Sellam","year":"2011","unstructured":"Sellam J, Hendel-Chavez H, Rouanet S, Abbed K, Combe B, Le Lo\u00ebt X et al (2011) B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. Arthritis Rheum 63:933\u2013938. https:\/\/doi.org\/10.1002\/art.30233","journal-title":"Arthritis Rheum"},{"key":"7390_CR27","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1136\/annrheumdis-2011-201109","volume":"71","author":"JE Gottenberg","year":"2012","unstructured":"Gottenberg JE, Ravaud P, Cantagrel A, Combe B, Flipo RM, Schaeverbeke T et al (2012) Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the \u201cOrencia and Rheumatoid Arthritis\u201d registry. Ann Rheum Dis 71:1815\u20131819. https:\/\/doi.org\/10.1136\/annrheumdis-2011-201109","journal-title":"Ann Rheum Dis"},{"key":"7390_CR28","first-page":"455","volume":"38","author":"E Alemao","year":"2020","unstructured":"Alemao E, Postema R, Elbez Y, Mamane C, Finckh A (2020) Presence of anti-cyclic citrullinated peptide antibodies is associated with better treatment response to abatacept but not to TNF inhibitors in patients with rheumatoid arthritis: a meta-analysis. Clin Exp Rheumatol 38:455\u2013466","journal-title":"Clin Exp Rheumatol"},{"key":"7390_CR29","doi-asserted-by":"publisher","first-page":"CD008794","DOI":"10.1002\/14651858.CD008794.pub2","volume":"2011","author":"JA Singh","year":"2011","unstructured":"Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK et al (2011) Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011:CD008794. https:\/\/doi.org\/10.1002\/14651858.CD008794.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"7390_CR30","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1136\/annrheumdis-2013-203843","volume":"73","author":"M Schiff","year":"2014","unstructured":"Schiff M, Weinblatt ME, Valente R, van der Heijde D, Citera G, Elegbe A et al (2014) Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis 73:86\u201394. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203843","journal-title":"Ann Rheum Dis"},{"key":"7390_CR31","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1136\/annrheumdis-2015-207942","volume":"75","author":"J Sokolove","year":"2016","unstructured":"Sokolove J, Schiff M, Fleischmann R, Weinblatt ME, Connolly SE, Johnsen A et al (2016) Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial. Ann Rheum Dis 75:709\u2013714. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207942","journal-title":"Ann Rheum Dis"},{"key":"7390_CR32","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s40744-019-00174-7","volume":"6","author":"R Fleischmann","year":"2019","unstructured":"Fleischmann R, Weinblatt M, Ahmad H, Maldonado MA, Alemao E, Ye J et al (2019) Efficacy of abatacept and adalimumab in patients with early rheumatoid arthritis with multiple poor prognostic factors: post hoc analysis of a randomized controlled clinical trial (AMPLE). Rheumatol Ther 6:559\u2013571. https:\/\/doi.org\/10.1007\/s40744-019-00174-7","journal-title":"Rheumatol Ther"},{"key":"7390_CR33","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s13075-021-02607-7","volume":"23","author":"W Rigby","year":"2021","unstructured":"Rigby W, Buckner JH, Louis Bridges S, Nys M, Gao S, Polinsky M et al (2021) HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA. Arthritis Res Ther 23:245. https:\/\/doi.org\/10.1186\/s13075-021-02607-7","journal-title":"Arthritis Res Ther"},{"key":"7390_CR34","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1136\/annrheumdis-2013-203993","volume":"74","author":"P Emery","year":"2015","unstructured":"Emery P, Gottenberg JE, Rubbert-Roth A, Sarzi-Puttini P, Choquette D, Taboada VMM et al (2015) Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. Ann Rheum Dis 74:979\u2013984. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203993","journal-title":"Ann Rheum Dis"},{"key":"7390_CR35","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1016\/S0140-6736(16)31651-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Burmester G-R, Combe B, Curtis JR, Hall S, Haraoui B et al (2016) Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. Lancet Lond Engl 388:2763\u20132774. https:\/\/doi.org\/10.1016\/S0140-6736(16)31651-8","journal-title":"Lancet Lond Engl"},{"key":"7390_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002817","volume":"9","author":"F Motta","year":"2023","unstructured":"Motta F, Bizzaro N, Giavarina D, Franceschini F, Infantino M, Palterer B et al (2023) Rheumatoid factor isotypes in rheumatoid arthritis diagnosis and prognosis: a systematic review and meta-analysis. RMD Open 9:e002817. https:\/\/doi.org\/10.1136\/rmdopen-2022-002817","journal-title":"RMD Open"},{"key":"7390_CR37","doi-asserted-by":"publisher","unstructured":"Brevet P, Boyer O, Vittecoq O, Freret M (2024) Immune reactivity directed against the carbamylated fibrinogen \u03b1 chain does not cross-react with citrullinated fibrinogen immunodominant peptides in rheumatoid arthritis patients. RMD Open 10(4):e004746. In press.https:\/\/doi.org\/10.1136\/rmdopen-2024-004746","DOI":"10.1136\/rmdopen-2024-004746"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07390-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07390-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07390-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T10:54:57Z","timestamp":1744455297000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07390-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,10]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["7390"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07390-3","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,10]]},"assertion":[{"value":"4 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}